Christopher Fenimore serves as the Executive Vice President, Finance and Chief Financial Officer at Regeneron Pharmaceuticals Inc., a leading biotechnology company focused on developing innovative medicines for serious diseases. In his role, Fenimore is responsible for overseeing the company's financial strategies and operations, ensuring fiscal responsibility and growth. He has been instrumental in guiding Regeneron through significant periods of expansion and development, leveraging his extensive experience in finance and strategic planning to enhance the company's performance and shareholder value. Before joining Regeneron, Fenimore held several key positions in the finance sector, showcasing his expertise and leadership. He previously served as the Chief Financial Officer at another prominent biopharmaceutical company, where he successfully managed financial operations and contributed to the company's growth trajectory. Fenimore's career also includes roles in investment banking and corporate finance, where he honed his skills in financial analysis, risk management, and strategic decision-making. His diverse background has equipped him with a comprehensive understanding of the financial landscape, enabling him to effectively navigate the complexities of the biotechnology industry. At Regeneron, Fenimore's achievements include playing a pivotal role in the company's successful IPO and subsequent financings, which have been crucial for funding research and development initiatives. His strategic foresight and financial acumen have helped Regeneron maintain a strong financial position, even amidst the challenges of developing and commercializing new therapies. Under his leadership, the company has continued to invest in groundbreaking research, leading to the development of several life-changing treatments. Fenimore's contributions have not only solidified Regeneron's standing in the industry but have also positioned the company for future success and innovation.